| Identification | Back Directory | [Name]
oxypaeoniflora | [CAS]
39011-91-1 | [Synonyms]
Nsc258310
Oxypeoniflorin
oxypaeoniflora
oxypaeoniflorin
Oxypaeoniflorin, >98%
β-D-Glucopyranoside, (1aR,2S,3aR,5R,5aR,5bS)-tetrahydro-5-hydroxy-5b-[[(4-hydroxybenzoyl)oxy]methyl]-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta[cd]pentalen-1a(2H)-yl
[[(1aR)-3aβ,5,5aβ,5b-Tetrahydro-5β-hydroxy-5bβ-[[(4-hydroxybenzoyl)oxy]methyl]-2-methyl-2α,5-methano-3,4-dioxa-1H-cyclobuta[cd]pentalen]-1aβ(2H)-yl]β-D-glucopyranoside | [Molecular Formula]
C23H28O12 | [MDL Number]
MFCD00869478 | [MOL File]
39011-91-1.mol | [Molecular Weight]
496.462 |
| Chemical Properties | Back Directory | [Melting point ]
>162°C (dec.) | [Boiling point ]
737.1±60.0 °C(Predicted) | [density ]
1.71±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
8.16±0.15(Predicted) | [color ]
White to Pale Yellow | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
Oxypaeoniflora is a plant extract of Paeonia suffruticosa, and has been used in the prevention of pathogenesis diabetic nephropathy providing anti-oxidative and anti-inflammatory activity. | [Definition]
ChEBI: Oxypaeoniflorin is a monoterpene glycoside with formula C23H28O12, isolated from several species of Paeoniae. It has a role as a plant metabolite. It is a cyclic acetal, a lactol, a bridged compound, a beta-D-glucoside, a 4-hydroxybenzoate ester and a monoterpene glycoside. | [in vivo]
Oxypaeoniflorin (OPA; 10-40 mg/kg; intragastrical administration; every day; for 30 days) treatment significantly reduces disruption of cardiac function and improves the indicators of ejection fraction (EF) and fractional shortening (FS). Oxypaeoniflorin significantly reduces the release of myocardial infarction-related factors, such as the creatine kinase (CK-MB), cardiac troponin I (cTnI) and cardiac troponin T (cTnT)[1]. | Animal Model: | C57BL/6 male mice (6-8 weeks of age, 20-25 g) bearing myocardial ischemia/reperfusion (MI/R) injury[1] | | Dosage: | 10 mg/kg, 20 mg/kg, 40 mg/kg | | Administration: | Intragastrical administration; every day; for 30 days | | Result: | Significantly reduced disruption of cardiac function and improved the indicators of ejection fraction (EF) and fractional shortening (FS). |
|
|
|